Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 16/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.64 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15229984 | 0.89 | METAP2 (0.70) | METAP2CYP1A2TDO2PSEN1PSEN2 | |
| SCHEMBL15230006 | 0.88 | METAP2 (0.63) | METAP2CYP1A2TDO2PSEN1PSEN2 | |
| SCHEMBL15230228 | 0.87 | METAP2 (0.61) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230236 | 0.86 | METAP2 (0.68) | METAP2CYP1A2TDO2 | |
| SCHEMBL15229865 | 0.85 | METAP2 (0.69) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230757 | 0.81 | METAP2 (1.00) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230186 | 0.80 | METAP2 (0.55) | METAP2CYP1A2TDO2KDM4EALDH1A1 | |
| SCHEMBL15230255 | 0.80 | METAP2 (0.55) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230132 | 0.78 | METAP2 (0.79) | METAP2CYP1A2TDO2 | |
| SCHEMBL15230130 | 0.78 | METAP2 (0.73) | METAP2CYP1A2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-9434743-B2 | Indazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005232-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130855-A1 | INDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005232-A1 | INDAZOLE DERIVATIVES | GPR119, INSR, INSRR | METAP2 46/4885CYP1A2 6/4885TDO2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.